Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure

Posted On: 2020-11-23 01:50:32 (Time Zone: Arizona, USA)


The oral antiviral medication Favipiravir, that prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with mild to moderate COVID-19. These findings were observed in a randomized, controlled Phase 3 clinical study conducted by Glenmark Pharmaceuticals, and the results are now published online in The International Journal of Infectious Diseases (IJID). The IJID is a globally reputed, peer-reviewed, pubmed indexed, open access journal published monthly by the International Society for Infectious Diseases, USA. The published findings will also appear in the print edition of the journal in the coming weeks.

The publication on the study titled "Efficacy and Safety of Favipiravir, an Oral RNADependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial" was authored by Dr. Zarir .F. Udwadia and other co-authors.

The link to the article is mentioned below

https://authors.elsevier.com/sd/article/S1201-9712(20)32453-X

https://www.sciencedirect.com/science/article/pii/S120197122032453X

The Phase 3 study with antiviral drug Favipiravir, brand name FabiFlu®, was conducted in 150 patients as part of a randomised, open label, multicenter, Phase 3 study. The study aimed to evaluate the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19.

Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy. Additionally, patients of confirmed COVID-19 with moderate symptoms were discharged from hospital earlier than those patients that did not receive Favipiravir, with the median time to clinical cure reduced by 2.5 days compared with the control group.

Dr Zarir F. Udwadia. MD, FRCP, FCCP, Breach Candy Hospital, Mumbai commented "Every claim for the efficacy of a new drug in COVID-19 must be backed by evidence from a clinical trial. Glenmark has done just that with Favipiravir. Their well-designed trial in 150 patients showed Favipiravir resulted in a significantly improved time to clinical cure and rapid viral clearance. Based on this I would consider the use of this anti-viral drug in symptomatic patients with mild to moderate COVID-19. I eagerly await the results of similar trials presently being conducted in Boston and at Stanford".

Since it was first pronounced a pandemic by the WHO in March, COVID-19 has continued to impact the lives of millions of people globally. As of date, over 50 mn. cases have been reported, with over 1 mn. deaths attributed to this disease. The virus has reportedly spread to all around the world and territories across the globe.i Most disease cases are mild to moderate, with symptoms including fever, cough and breathlessness. In severe cases, COVID-19 can cause pneumonia, severe acute respiratory syndrome, kidney failure and death.ii

Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby halting the virus's replication cycle. This helps control the multiplication of the virus and prevents its spread in the patient. This mechanism of action of Favipiravir is novel compared to most antivirals that primarily prevent entry and exit of the virus from cells. Several published reports are now available of the drug's effectiveness against COVID-19.

Mr. Robert Crockart, Chief Commercial Officer Glenmark Pharmaceuticals said, "From the first reported case of COVID-19, our every effort was to bring a viable, safe and effective treatment option to patients in a timely manner. It is encouraging to see our trial results now published in a reputed global medical journal, which we hope will support other countries in their fight against this disease."

Patients in the Glenmark clinical trial received Favipiravir tablets 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, along with standard supportive care. Randomization was stratified based on disease severity into mild and moderate. Favipiravir was well tolerated with no serious adverse events (SAEs) or deaths in the Favipiravir treated arm.

The pre-specified primary endpoint, time from randomisation to cessation of oral shedding of the SARS-CoV-2 virus, demonstrated a 2 day earlier virological cure in the Favipiravir treatment group, though not statistically significant. However, significant improvement in time to clinical cure and other secondary end-points suggest Favipiravir may be beneficial in the treatment of mild-to-moderate COVID-19.

"The study, which was undertaken by Glenmark Pharmaceuticals, at a time when the number of cases for infections were dramatically increasing around the globe, demonstrates Glenmark's commitment to ensuring all patients have access to affordable medication, to make a positive impact on their quality of life," said Dr. Monika Tandon, Sr. Vice President & Head - Clinical Development, Global Specialty/Branded Portfolio at Glenmark.

In June 2020, Glenmark received manufacturing and marketing approval from India's drug regulator for Favipiravir (FabiFlu®), making it the first oral approved medication in India for the treatment of mild to moderate COVID-19. The manufacturing and marketing approval was granted as part of an accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India. The approval's restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.481.45 as compared to the previous close of Rs. 482.7. The total number of shares traded during the day was 69677 in over 1989 trades.

The stock hit an intraday high of Rs. 486.6 and intraday low of 478.3. The net turnover during the day was Rs. 33565841.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Zensar Technologies Ltd Board approves interim dividend of Rs. 1.20

SVP Global Ventures Limited announces Q3FY21 results

Josts Engineering Company Ltd board to consider stock split

Emerald Leasing Finance and Investment Company Limited board approves 42:19 rights issue

Mphasis Ltd Q3FY21 consolidated net profit jumps to Rs. 325.52 crore

Bliss GVS Pharma Ltd Q3FY21 consolidated net profit climbs to Rs. 25.55 crore

National Standard India Ltd Q3 net profit at Rs. 1.72 crore

Zensar Technologies Ltd posts Rs. 137.89 crore consolidated PAT in Q3FY21

Indian Energy Exchange Ltd board approves interim dividend of Rs. 2.50 for FY2020-21

AU Bank forays into Odisha with its branch launch in Bhubaneswar

Nakoda Group of Industries Ltd board approves 5:8 bonus issue

MCX reports consolidated PAT of Rs. 71.80 crore in Q3 FY2020-21

Supreme Petrochem Ltd posts jump in Q3FY21 PAT to Rs. 171.52 crore

Cyient Limited posts Rs. 95.4 crore consolidated PAT in Q3FY21

Indian Energy Exchange Ltd Q3FY21 consolidated net profit rises to Rs. 58.14 crore

Radio City Ad-volumes grow by 9% in Q3 FY21 as compared to same period previous year

National General Industries Limited has sold its steel casting unit

Advitiya Trade India Limited starts operations of Aluminum panel

SBI Card and Payment Services Ltd Q3FY21 net profit at Rs. 209.65 crore

Get Instant In-Principle Sanction on Kotak Digi Home Loans

Sangam India Ltd posts consolidated PAT of Rs. 7.43 crore in Q3FY21

South India Bank Ltd Q3FY21 loss at Rs. 91.62 crore

JK Tyre & Industries Ltd Q3FY21 consolidated PAT zooms to Rs. 224.09 crores

Neelamalai Agro Industries Ltd board approves buyback of 25,350 shares at Rs. 1600 per share

Manappuram Finance to raise Rs. 600 crore through private placement of NCDs

Bajaj Holdings & Investment Ltd Q3FY21 consolidated net profit climbs to Rs. 1149.58 crore

SRF Limited board declares interim dividend of Rs. 19

Bandhan Bank Limited - Key Highlights - Q3FY21

Cabinet approves the Investment Proposal of Rs. 5281.94 crore for 850 MW Ratle Hydro Power Project

Infosys named a Leader in the IDC MarketScape for Asia/Pacific Salesforce Implementation Services 2020 Vendor Assessment

IIFL Securities Ltd posts consolidated PAT of Rs. 50.58 crore in Q3

SRF Ltd Q3FY21 consolidated net profit at Rs. 324.73 crore

Genus Power Infrastructures Ltd Q3FY21 consolidated PAT zooms to Rs. 28.83 crore

Vardhman Textiles Ltd Q3FY21 consolidated PAT at Rs. 170.52 crore

Rajratan Global Wire Ltd to increase capacity of Rajratan Thailand

Everest Group names Persistent a Major Contender in its Salesforce Healthcare Services PEAK Matrix® Assessment 2021

JSPL Q3FY21 consolidated PAT jumps to Rs. 2254.66 crore

Kabra Extrusiontechnik Ltd Q3FY21 consolidated net profit at Rs. 5.80 crore

Bandhan Bank Ltd Q3FY21 net profit lower at Rs. 632.59 crore

Bajaj Auto Ltd Q3 FY2020-21 consolidated PAT jumps to Rs. 1716.26 crore

Asian Paints Ltd reports consolidated net profit of Rs. 1238.34 crore in Q3FY21

Ashoka Buildcon receives NOA for Solar Project on EPC Basis from NTPC

Indo Count Industries Ltd reports consolidated net profit of Rs. 92.92 crores in Q3 FY2020-21

Westlife Development Ltd posts Rs. 0.11 crore consolidated PAT in Q3FY21

Kajaria Ceramics Ltd board approves interim dividend of Rs. 10

Freshtrop Fruits Limited board to consider buyback proposal on Jan 28, 2021

Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director

NALCO board to consider buyback proposal on Jan 27, 2021

Kajaria Ceramics Ltd Q3FY21 consolidated PAT rises to Rs. 118.94 crore

Apollo Tricoat Tubes Ltd Q3FY21 PAT surges to Rs. 37.89 crore



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020